Table 1 .
Baseline Characteristics
| Frequency | |
|---|---|
| Median age | 57.5 (range: 28–68) |
| Condition | |
| ALL | 1 |
| AML | 4 |
| MDS | 1 |
| MM | 1 |
| MPD | 2 |
| NHL | 1 |
| Remission status | |
| Complete remission (CR) | 2 |
| Not in CR | 8 |
| Cell source | |
| PBSCT | 10 |
| BMT | 0 |
| Donor relation | |
| Related donor | 4 |
| Unrelated donor | 6 |
| HLA matching | |
| 10/10 | 8 |
| 9/10 | 2 |
| Recipient/donor sex | |
| Female/female | 3 |
| Female/male | 1 |
| Male/female | 1 |
| Male/male | 5 |
| Conditioning regimen | |
| Flu/Bu | 5 |
| Flu/Bu/ATG | 2 |
| Flu/Bu/Rituxan | 1 |
| Flu/Mel | 1 |
| Pento/BU/Rituxan | 1 |
| aGVHD prophylaxis | |
| TAC/MTX | 7 |
| TAC/MMF | 3 |
| Donor/recipient CMV | |
| Neg/neg | 4 |
| Neg/pos | 3 |
| Pos/pos | 3 |
| aGVHD onset date (median) | 3.86 weeks (range: 2.14–14.71) |
| Overall aGVHD onset grade* | |
| I | 0 |
| II | 9 |
| III | 1 |
| IV | 0 |
| aGVHD onset organ stage | |
| Skin | |
| 1 | 2 |
| 2 | 1 |
| 3 | 2 |
| 4 | 0 |
| GI | |
| 1 | 7 |
| 2 | 1 |
| 3 | 0 |
| 4 | 0 |
| Liver | |
| 1 | 1 |
| 2 | 0 |
| 3 | 0 |
| 4 | 0 |
ALL indicates acute lymphoblastic leikemia; AML, acute myelogenous leukemia; MDS, myelodysplastic syndromes; MM, multiple myeloma; MPD, myeloproliferative disorder; NHL, non-Hodgkin’s lymphoma; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; GI, gastrointestinal; CMV, cytomegalovirus; PBSCT, peripheral blood stem cell transplantation; BMT, bone marrow transplantation; Tac/MMF, tacrolimus/mycophenolate mofetil; Tac/MTX, tacrolimus/methotrexate; Flu/Mel, fludarabine and melphalan; Flu/Bu, fludarabine and busulfan; Flu/Bu/ATG, fludarabine, busulfan, and antithymocyte globulin.
*
All cases of aGVHD were biopsy confirmed.